Analyzing Q BioMed (OTCMKTS:QBIO) and Virios Therapeutics (NASDAQ:VIRI)

Q BioMed (OTCMKTS:QBIO) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Profitability

This table compares Q BioMed and Virios Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Q BioMed	N/A	N/A	N/A
Virios Therapeutics	N/A	-130.33%	-115.00%

Insider and Institutional Ownership

9.1% of Virios Therapeutics shares are owned by institutional investors. 28.2% of Q BioMed shares are owned by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Q BioMed and Virios Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q BioMed	0	0	0	0	0.00
Virios Therapeutics	0	1	1	0	2.50

Virios Therapeutics has a consensus price target of $3.00, indicating a potential downside of 59.62%. Given Virios Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Virios Therapeutics is more favorable than Q BioMed.

Valuation and Earnings

This table compares Q BioMed and Virios Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q BioMed	$280,000.00	0.16	-$2.05 million	N/A	N/A
Virios Therapeutics	N/A	N/A	-$5.30 million	($0.27)	-27.52

Q BioMed has higher revenue and earnings than Virios Therapeutics.

Volatility and Risk

Q BioMed has a beta of 1.95, suggesting that its share price is 95% more volatile than the S&P 500. Comparatively, Virios Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500.

Summary

Q BioMed beats Virios Therapeutics on 6 of the 10 factors compared between the two stocks.

About Q BioMed

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

About Virios Therapeutics

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.